Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26915876 | 0.88 | NPC1 (0.36) | NPC1L3MBTL1DGAT1F2RL1KLKB1 | |
| SCHEMBL2965634 | 0.85 | NPC1 (0.39) | NPC1L3MBTL1DGAT1F2RL1KLKB1 | |
| SCHEMBL2965865 | 0.84 | CYP2C9 (0.42) | NPC1L3MBTL1DGAT1MAPTS1PR4 | |
| SCHEMBL24723912 | 0.81 | DGAT1 (0.35) | NPC1DGAT1F2RL1KLKB1 | |
| SCHEMBL26915819 | 0.80 | F2RL1 (0.33) | NPC1DGAT1F2RL1 | |
| SCHEMBL18339054 | 0.80 | NPC1 (0.33) | NPC1DGAT1F2RL1 | |
| SCHEMBL26915678 | 0.78 | DGAT1 (0.34) | NPC1DGAT1F2RL1 | |
| SCHEMBL15779031 | 0.78 | NPC1 (0.40) | NPC1DGAT1 | |
| SCHEMBL18339058 | 0.78 | MEN1 (0.39) | NPC1DGAT1MAPTALDH1A1RAB9A | |
| SCHEMBL24724723 | 0.78 | NPC1 (0.41) | NPC1L3MBTL1DGAT1KLKB1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| CN-117715909-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-03-15 | — | — | CN | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | NPC1 95/4885L3MBTL1 4523/4885DGAT1 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.